Real-world effectiveness of tezepelumab on clinical remission and small airway dysfunction

A prospective, multicentre study of 39 adults with severe asthma treated with tezepelumab for 12 months. The research measured clinical remission rates and small airway dysfunction using oscillometric parameters. The dataset was authored by Francesco Menzella and last updated in May 2026.

Use Cases

• Analyze the real-world effectiveness of tezepelumab based on clinical remission criteria.
• Study the dissociation between clinical symptoms and physiological small airway dysfunction based on oscillometric parameters.
• Compare remission rates in patients with and without baseline small airway dysfunction.
• Investigate the impact of complete oral corticosteroid withdrawal on severe exacerbation rates.

Strengths

• Prospective study design with a 12-month follow-up period.
• Includes 39 adult patients with severe asthma.
• Defines clinical remission using specific SANI criteria.
• Reports specific remission rates: 77.4% overall and 80.0% for patients with baseline SAD.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The cohort size of 39 patients is relatively small.

Provenance

Source

Francesco Menzella via figshare.

Collection Method

Prospective, multicentre clinical study.

Time Range

Study duration of 52 weeks (12 months).

Freshness

Last updated 2026-05-27 16:26:07; freshness should be verified.